The pharmaceutical industry is at a technology inflection point that will determine competitive hierarchies for the next twenty years. Artificial intelligence is compressing drug discovery timelines from decades to years. Cell and gene therapies are delivering single-administration cures for diseases that previously required lifetime treatment. Antibody-drug conjugates are combining the targeting precision of biologics with the cell-killing power of cytotoxic chemotherapy. Radiopharmaceuticals are emerging as a fourth pillar of oncology treatment. And RNA-based medicines are unlocking target classes previously considered undruggable.
AstraZeneca’s ADC portfolio built through the Daiichi Sankyo partnership for Enhertu is the most commercially successful technology bet in recent pharmaceutical history. Eli Lilly’s decade-long investment in incretin biology produced Mounjaro and Zepbound. Roche’s early commitment to companion diagnostics and precision oncology defined its competitive position in cancer for a generation. The technology integration choices being made today will have comparable consequences.
Emerging Technologies Assessed: AI in Drug Discovery / Cell and Gene Therapy / Antibody-Drug Conjugates / Radiopharmaceuticals / mRNA and RNA Therapeutics / Precision Medicine and Biomarker-Driven Development / Digital Health and Real-World Evidence
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Table of Contents
1. Executive Summary
2. Pharmaceutical Technology Landscape Overview
3. Emerging Technology Deep Dives
3.1 AI in Drug Discovery
3.2 Cell and Gene Therapy
3.3 Antibody-Drug Conjugates
3.4 Radiopharmaceuticals
3.5 mRNA and RNA Therapeutics
3.6 Precision Medicine
3.7 Digital Health and Real-World Evidence
4. Technology Integration Strategies — Ten Leading Companies
5. Platform Architecture and Pipeline Strategy
6. Competitive Landscape
7. Regional Adoption of Emerging Technologies
8. Investment and Partnership Opportunities
9. Strategic Conclusions and Recommendations
10. Appendix
List of Tables
Table 1. Pharmaceutical Emerging Technologies — Modality Maturity Assessment 2025
Table 2. AI in Drug Discovery — Platform Comparison 2025
Table 3. Cell and Gene Therapy — Clinical Pipeline 2025
Table 4. ADC Pipeline Summary 2025
Table 5. Radiopharmaceuticals — Clinical Pipeline 2025
Table 6. mRNA and RNA Therapeutics — Platform Comparison 2025
Table 7. Precision Medicine — CDx Programs 2025
Table 8. World’s Leading Companies — Emerging Technology Investment 2025
Table 9. World’s Leading Companies — M&A in Emerging Technologies 2023-2025
Table 10. World’s Leading Companies — Technology Portfolio Architecture
Table 11. Biotech Ecosystem — Key Partners and Acquisition Targets 2025
Table 12. Regulatory Pathways for Emerging Modalities 2025
Companies Profiled
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Pfizer
Novartis
Johnson & Johnson
Daiichi Sankyo
Seagen
AbbVie
